Whole Genome Sequencing: What to Know Before Ordering

Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.

Whole genome sequencing is the broadest commonly available DNA test: it reads nearly all of a person’s genetic code rather than checking one gene, a small panel of genes, or a limited set of ancestry markers. That breadth can be useful when a person has an unexplained medical condition, a complex family history, or prior genetic testing that did not provide an answer. It also makes the test easy to overestimate. A genome sequence is not a crystal ball, not every finding is medically meaningful, and the same raw data can produce very different reports depending on the laboratory’s quality controls, interpretation pipeline, and clinical context.

This guide explains what to know before ordering whole genome sequencing, including the difference between clinical and consumer testing, what results can mean, what WGS can miss, how to prepare, what questions to ask about cost and privacy, and when a genetics professional should be involved.

What is whole genome sequencing?

Whole genome sequencing, often abbreviated WGS, analyzes DNA across nearly the entire genome. The genome includes protein-coding genes, non-coding regions that may regulate genes, mitochondrial DNA in many tests, and large stretches of DNA whose medical meaning is still being studied. MedlinePlus Genetics describes whole genome sequencing and whole exome sequencing as technologies used to identify genetic variations across large amounts of DNA, with whole genome sequencing covering more of the genome than exome sequencing.

Most people encounter WGS in one of three settings:

• Clinical diagnostic testing: ordered by a clinician, often through a genetics clinic, when there is a medical question such as a suspected inherited disorder.
• Consumer or elective sequencing: ordered online, usually with at-home saliva or cheek-swab collection, for health-risk, ancestry, trait, wellness, or raw-data access.
• Research sequencing: performed as part of a study; results may not be returned, may not be clinically confirmed, and may not be suitable for medical decisions.

The technology is powerful because it can look broadly instead of testing one hypothesis at a time. However, the medical value comes less from “reading all the DNA” and more from the analysis: which regions are reliably covered, which variant types are called, which genes are interpreted, what clinical information is supplied, and whether the report is reviewed by qualified genetics professionals.

Whole genome vs exome, gene panel, microarray, and 23andMe-style tests

Different genetic tests answer different questions. A broader test is not automatically better; sometimes a targeted test is faster, cheaper, easier to interpret, or better validated for a specific condition.

Test type	What it looks at	Common use	Key limitation
Single-gene test	One gene	When a specific condition is strongly suspected	Misses causes in other genes
Gene panel	A curated set of genes for one clinical area	Inherited cancer, cardiomyopathy, epilepsy, hearing loss, pharmacogenomics	Panel content varies and may miss newly discovered genes or non-panel conditions
Chromosomal microarray	Large copy-number gains and losses across the genome	Developmental delay, congenital anomalies, autism evaluation in some settings	Does not read single-letter sequence changes well
Whole exome sequencing	Most protein-coding regions, roughly the exons	Suspected rare genetic disease when the cause is unclear	May miss non-coding variants and some structural or coverage-dependent findings
Whole genome sequencing	Most coding and non-coding DNA	Broad diagnostic evaluation, prior negative testing, elective genomic data access	Interpretation is complex; not all detected variants are meaningful or reportable
Genotyping array	Selected known markers, not a full sequence	Ancestry, traits, limited health-risk screening	Does not sequence the genome and can miss many clinically relevant variants

The CDC notes that healthcare providers may recommend exome or whole genome sequencing for complex medical conditions or rare disorders when other testing has not found a cause. For certain pediatric patients with congenital anomalies, developmental delay, or intellectual disability, an American College of Medical Genetics and Genomics guideline strongly recommends considering exome or genome sequencing as a first- or second-tier test.

Who should consider whole genome sequencing?

WGS is most likely to be medically useful when there is a clear question. Examples include a child with unexplained developmental delay or multiple congenital anomalies, an adult with a suspected rare inherited condition, a family with several relatives affected by a similar disorder, or a person whose prior panel or exome testing was nondiagnostic. In these situations, genome sequencing may find a pathogenic variant, identify a condition that changes management, clarify reproductive risk, or guide testing for relatives.

For healthy adults, the decision is more preference-sensitive. Some people want to learn about medically actionable inherited risks, pharmacogenomic markers, carrier status, ancestry, or wellness traits. Others prefer not to know results that may be uncertain, anxiety-provoking, or difficult to act on. The benefits are greatest when the test includes pre-test education, informed consent, a clear reporting scope, and access to post-test counseling.

Research on diagnostic yield varies by patient group. In pediatric patients with suspected genetic disorders, one systematic review and meta-analysis reported pooled diagnostic yield estimates in the high 30% range for both genome and exome sequencing, with WGS showing advantages in some comparisons. Another review of rare disease studies found diagnostic yield varied substantially depending on whether genome sequencing was used first-line or after prior testing. These studies support WGS as a valuable diagnostic tool, but they also show why a negative result is common and why test selection should fit the clinical scenario.

How whole genome sequencing results are interpreted

A WGS report is not simply a list of every DNA difference. Every person has millions of variants compared with a reference genome, and most are harmless. Clinical laboratories filter and interpret variants using evidence such as population frequency, predicted effect on a gene or protein, published disease associations, inheritance pattern, segregation in the family, and whether the person’s symptoms match the gene-disease relationship.

Clinical variant interpretation commonly uses categories established by professional standards: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. The widely used ACMG/AMP sequence-variant interpretation standards explain this five-tier framework. A “pathogenic” or “likely pathogenic” result may support a diagnosis when it fits the clinical picture. A “variant of uncertain significance,” often called a VUS, means the evidence is not strong enough to classify the variant as disease-causing or benign.

Clinical WGS reports may include:

• Primary findings: results related to the reason the test was ordered.
• Secondary findings: medically actionable variants in genes unrelated to the original reason for testing, if the patient chooses to receive them and the lab offers them.
• Carrier findings: variants that may matter for reproductive planning, especially for recessive or X-linked conditions.
• Pharmacogenomic findings: variants that may affect response to certain medications, though prescribing decisions still require clinical review.
• Raw data files: FASTQ, BAM/CRAM, or VCF files, depending on the provider. These are data files, not interpreted medical reports.

The ACMG maintains recommendations for reporting certain secondary findings in clinical exome and genome sequencing. The current framework focuses on genes where pathogenic variants may indicate risks for conditions such as hereditary cancer syndromes, certain heart conditions, and other disorders where surveillance or prevention may be possible. Patients should ask whether secondary findings are included, optional, or excluded, and whether minors will receive adult-onset risk findings.

What whole genome sequencing can miss

“Whole genome” does not mean “detects everything.” Short-read WGS, the common technology used in many clinical and consumer tests, may have difficulty with repetitive regions, pseudogenes, certain structural rearrangements, repeat expansions, methylation disorders, low-level mosaicism, mitochondrial heteroplasmy below a lab’s threshold, and variants in regions with poor or uneven coverage. Some of these findings require specialized tests, long-read sequencing, optical genome mapping, methylation testing, RNA sequencing, chromosomal testing, or targeted assays.

WGS can also miss a diagnosis because the variant is detected but not recognized as clinically meaningful. Gene-disease knowledge changes rapidly, and many variants have insufficient evidence. That is why reanalysis can be useful after a year or more, especially for people with a strong suspicion of a genetic condition and nondiagnostic results.

Limitations are especially important for consumer testing. The FDA explains that direct-to-consumer tests vary by risk and intended use, and tests used for moderate- to high-risk medical purposes generally require stronger review of claims. MedlinePlus also notes that direct-to-consumer genetic testing can offer useful information but has limitations, including incomplete variant coverage and the possibility that results may not provide a definitive answer about disease risk.

How to prepare before collecting a sample

Most WGS tests use saliva, a cheek swab, or blood. At-home kits usually include instructions not to eat, drink, smoke, chew gum, or brush teeth for a period before collection. Follow the kit instructions exactly, because contaminated or low-DNA samples can fail quality control and delay results.

Before ordering, gather information that improves interpretation:

• A three-generation family history, including ages of diagnosis and death when known.
• Prior genetic test reports, not just portal screenshots.
• Relevant clinical records, imaging, pathology, specialist notes, and lab results.
• Ethnicity or ancestry information, if you are comfortable sharing it, because population frequency data can affect variant interpretation.
• A list of medications if pharmacogenomic reporting is included.

If the test is for a child or an affected family member, ask whether trio testing is available. Trio testing analyzes the affected person and both biological parents. It can help determine whether a variant is inherited or de novo, which can improve diagnostic interpretation.

How much does whole genome sequencing cost?

Cost depends on whether the test is clinical or consumer, sequencing depth, included interpretation, required memberships, shipping, physician ordering fees, genetic counseling, insurance billing, and optional add-ons. A low advertised price may not be the final cost if a membership is required, shipping is added, or reports cost extra.

Comparison methodology: the table below compares publicly listed consumer-facing information by effective cost to the patient: base sequencing price plus mandatory membership or processing fees when stated, plus known mandatory shipping or handling when publicly listed. Optional expedited processing, optional subscriptions, optional reports, and financing costs are excluded unless noted. Prices and availability can change, so consumers should confirm the checkout total and current terms before purchasing.

Option type	Example public offer	What is included publicly	Effective cost considerations	Medical-use caveat
Consumer 30x WGS bundle	Sequencing.com	Public page lists a Standard bundle at $399 and Professional bundle at $799, 30x sequencing, at-home swab, free worldwide shipping, downloadable data, and regular processing included. Expedited processing is listed as an add-on.	Listed total for Standard regular processing is $399 with free shipping; expedited and ultra-rapid processing add cost. The page states a subscription is not required and that users can move to a free plan while keeping included data and reports.	Consumer health reports should be reviewed with a qualified professional before medical action.
Consumer WGS with required first-year membership	DNA Complete / Nebula Genomics terms	Terms list 1x Essential, 30x Pro, and 100x Elite WGS products with annual membership tied to reporting and ongoing processing.	Terms list 1x at $245 with $95 annual renewal, 30x at $595 with $195 annual renewal, and 100x at $1,295 with $495 annual renewal. Shipping and handling are added at checkout; membership must be canceled before renewal to avoid future charges.	Terms describe the service as not intended for diagnostic or treatment decisions without professional advice.
Clinical WGS ordered by a clinician	Hospital genetics clinic or clinical laboratory	Usually includes clinician ordering, medical indication, clinical report, and possible insurance billing or prior authorization.	Out-of-pocket cost may be $0, a copay/coinsurance/deductible amount, a self-pay price, or a patient-assistance amount depending on coverage and lab policy.	Most appropriate when WGS is being used to answer a medical diagnostic question.
Clinical genome-wide testing laboratory	Variantyx billing information	Public billing page describes insurance, Medicaid, Medicare-related considerations, self-pay options, preauthorization, appeals, and patient assistance.	Personalized cost depends on insurance and the ordered test. The page states patients are contacted if estimated out-of-pocket expense exceeds $100 and that self-pay may be available if insurance does not cover testing.	Results are released through the ordering healthcare provider, consistent with clinical testing workflow.

When comparing options, ask for the total checkout price, the first-year cost, the renewal cost, cancellation rules, whether raw data download is included, whether data storage requires an active subscription, and whether a clinical confirmation test would be needed for important findings.

Privacy, insurance, and family implications

Genomic data is uniquely identifying and can reveal information about biological relatives. Before ordering, read the privacy policy and consent form. Look for whether the company may use de-identified data for research, share data with third parties, respond to law-enforcement requests, store your sample, destroy your sample on request, or allow permanent data deletion.

In the United States, the Genetic Information Nondiscrimination Act, or GINA, provides federal protections against genetic discrimination in health insurance and employment. However, NHGRI explains that GINA does not cover life insurance, disability insurance, or long-term care insurance, and some groups and circumstances may fall outside its protections. If those issues matter to you, consider discussing timing and implications with a genetics professional or legal/insurance advisor before testing.

Questions to ask before ordering

• Is this clinical testing or educational consumer testing? If you need a diagnosis, choose a clinical pathway.
• Who orders the test? Some tests require a physician or genetic counselor; others are direct-to-consumer.
• Which lab performs sequencing and is it CLIA-certified for clinical testing? CLIA certification matters for U.S. clinical laboratory testing, but it does not by itself guarantee that every claim is clinically useful.
• What variant types are analyzed? Ask about single-nucleotide variants, small insertions/deletions, copy-number variants, structural variants, mitochondrial variants, repeat expansions, and pharmacogenomic markers.
• What is the sequencing depth? Many clinical and consumer WGS products advertise 30x average coverage; lower coverage may be useful for ancestry or research but is less suitable for many health interpretations.
• Are secondary findings included? Ask whether you can opt in or out.
• Will I receive raw data? If yes, ask which file types are included and whether there is a download fee.
• What happens after a positive or uncertain result? Ask whether genetic counseling, confirmatory testing, family testing, or clinician letters are available.
• What is the total cost? Include mandatory fees, subscriptions, shipping, provider visits, counseling, and future reanalysis.

What to do after results come back

For a medically significant result, do not make major treatment, screening, surgery, medication, or reproductive decisions based only on a consumer report or third-party interpretation. Share the full report with a clinician or genetic counselor. They may recommend confirming the variant in a clinical laboratory, testing relatives, updating screening, or correlating the result with personal and family history.

If the report is negative, keep a copy. A negative WGS result can still be useful because it documents what was assessed and may allow future reanalysis. If symptoms are ongoing, follow up with the clinician who ordered the test. The next step might be reanalysis, a different test type, RNA testing, metabolic testing, imaging, specialist evaluation, or testing another affected family member.

If the report includes a VUS, ask whether family testing could help clarify it. Do not assume the uncertain variant explains symptoms. Keep contact information current with the ordering clinic or lab if reclassification notices are offered.

FAQs about whole genome sequencing

Is whole genome sequencing worth it?

It can be worth it when there is a clear medical question, prior testing has not found an answer, or a clinician believes genome-wide analysis is appropriate. For healthy people ordering elective testing, value depends on goals, privacy comfort, willingness to handle uncertain results, and whether professional interpretation is available.

Can whole genome sequencing detect cancer?

Germline WGS can identify inherited variants that increase risk for some cancers, such as certain hereditary cancer syndromes, if the test analyzes and reports those genes. It does not diagnose an existing cancer. Tumor sequencing is a different test performed on cancer tissue or blood to study acquired variants in cancer cells.

Can WGS tell me which medications will work?

Some WGS reports include pharmacogenomic variants that may affect medication metabolism or response. These results are only one part of prescribing. Age, kidney and liver function, other medications, diagnosis, ancestry, allergies, and clinical guidelines all matter. Do not start, stop, or change medication based only on a genome report.

Is 30x coverage enough?

For many short-read WGS applications, 30x average coverage is commonly used because each base is read multiple times on average. But “average” coverage does not mean every region is covered equally. Some regions may be poorly covered, and some variant types require specialized methods regardless of depth.

Should children have whole genome sequencing?

Children may benefit from clinical WGS when they have symptoms suggesting a genetic condition, congenital anomalies, developmental delay, or other medical indications. Elective testing of healthy children for adult-onset conditions is more ethically complex because it may remove the child’s future choice about whether to know. Discuss pediatric testing with a genetics professional.

Can I use ancestry DNA raw data instead?

Ancestry-style genotyping data is not the same as WGS. It checks selected markers and may omit many medically relevant variants. Uploading genotyping data to third-party interpretation sites can produce misleading health claims and should not replace clinical testing when a medical question exists.

How long do results take?

Consumer WGS commonly takes several weeks after the lab receives a usable sample, and clinical testing timelines vary by urgency, insurance authorization, sample type, and analysis complexity. Rapid genome sequencing in hospital settings may be available for critically ill infants or children in specialized programs.

Bottom line

Whole genome sequencing can be a powerful test, but ordering it wisely requires matching the test to the question. If you are seeking a diagnosis, prioritize a clinical pathway with genetics expertise, transparent reporting, and a plan for follow-up. If you are ordering consumer WGS for personal learning, compare total cost, data access, subscription rules, privacy terms, and the difference between educational insights and clinical results. The most useful genome test is not simply the one that reads the most DNA; it is the one that provides reliable interpretation and clear next steps for your situation.

Sources and references

• MedlinePlus Genetics: What are whole exome sequencing and whole genome sequencing?
• CDC: Genetic Testing
• ACMG guideline: Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability
• ACMG/AMP standards and guidelines for interpretation of sequence variants
• FDA: Direct-to-Consumer Tests
• MedlinePlus Genetics: Pros and cons of direct-to-consumer genetic testing
• National Human Genome Research Institute: Genetic Discrimination and GINA
• Systematic review: WGS diagnostic yield in pediatric suspected genetic disorders
• npj Genomic Medicine: Evidence review for first-line genome sequencing in rare genetic disorders

This article is for general education and is not a diagnosis or personal medical advice. Genetic testing decisions and results should be discussed with a qualified healthcare professional, especially when symptoms, family history, reproductive planning, or treatment decisions are involved.